Sky Labs' Wearable Device "Apollon" Recognized as an Honoree in CES 2025 Innovation Awards

2024-11-18 Sky Labs HaiPress

SEOUL,South Korea,Nov. 18,2024 -- Sky Labs announced that its groundbreaking wearable device,Apollon,has been named an "Honoree" in the Artificial Intelligence category at the CES 2025 Innovation Awards. Hosted by the Consumer Technology Association (CTA)®,the CES Innovation Awards program annually recognizes outstanding achievements in design and engineering across 33 categories of consumer technology. This prestigious honor marks Sky Labs' second award at CES,underscoring the company's continued impact on health technology innovation.


CART BP pro(left) and Wearable Device ‘Apollon’ (right,project name)

Apollon is a pioneering wearable device designed for comprehensive monitoring of vital health indicators. Integrating both a wrist-worn module and a ring-type sensor,Apollon automatically and periodically measures SpO₂,irregular pulse,pulse rate,blood pressure,respiration rate,and skin temperature,while also offering on-demand body temperature measurements. Engineered with hospitalized patients in mind,Apollon supports extensive tracking of health data,providing valuable insights for health monitoring and treatment.

Apollon's innovative design includes a wrist-worn control module with an integrated monitor and a detachable ring-type sensor module,connected seamlessly for optimal user experience. The wristband is crafted from silicone,promoting hygienic use and enabling secure attachment and removal from the control module. Additionally,the single-sized silicone ring around the sensor module provides comfort and adaptability,allowing users of varying finger sizes to wear the sensor comfortably for extended periods. The hardware is streamlined with power,charging,and data transmission connectors on a single surface,optimizing its structure for enhanced ease of use.

In parallel with Apollon's success,Sky Labs' CART BP pro,a ring-type ambulatory blood pressure monitoring device,has been selected as the primary monitoring tool for an ambitious five-year cohort study led by the Korean Society of Hypertension,in celebration of their 30th anniversary. This large-scale CUFFLESS BP Registry-Outcome Study will incorporate CART BP pro to further research into innovative hypertension management strategies. The study aims to evaluate a range of clinical outcomes associated with hypertension and to explore advanced,non-invasive solutions for blood pressure management.

AboutSky Labs


Founded in September 2015,Sky Labs is a leading healthcare startup that has developed CART (Cardio Tracker),a ring-shaped medical device designed for disease monitoring using heart signals collected through optical sensors. Following this,the company developed CART BP,a cuffless,ring-shaped device that enables continuous 24-hour blood pressure monitoring,providing valuable treatment information and making a groundbreaking contribution to improving the quality of life for hypertension patients. Sky Labs has signed an exclusive domestic distribution agreement for CART BP with South Korea's Daewoong Pharmaceutical and is preparing for nationwide sales to hospitals,clinics,and general consumers.

Media Inquiries


Edelman Korea SkyLabs@edelman.com

Disclaimer: This article is reproduced from other media. The purpose of reprinting is to convey more information. It does not mean that this website agrees with its views and is responsible for its authenticity, and does not bear any legal responsibility. All resources on this site are collected on the Internet. The purpose of sharing is for everyone's learning and reference only. If there is copyright or intellectual property infringement, please leave us a message.

Newest

1Cangxi County Holds 2026 New Year's Cultural Performance for the Public

Cangxi County Holds 2026 New Year's Cultural Performance for the Public

2The First Series of the World Chinese Medicine Forum in 2025 Concludes Successfully

The First Series of the World Chinese Medicine Forum in 2025 Concludes Successfully

3The Second Series of the World Chinese Medicine Forum in 2025 Concludes Successfully

The Second Series of the World Chinese Medicine Forum in 2025 Concludes Successfully

4Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Singapore College of Traditional Chinese Medicine Sign Strategic Cooperation Framework Agreement on TCM Education and Exchange

Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Singapore College of Traditional Chinese Medicine Sign Strategic Cooperation Framework Agreement on TCM Education and Exchange

5Tianjiang Pharmaceutical, a Subsidiary of China TCM, Participates in the 4th CACM Specialized Disease Collaboration Platform Annual Conference & 10th Jiangsu Traditional Chinese Medicine Academic Conference

Tianjiang Pharmaceutical, a Subsidiary of China TCM, Participates in the 4th CACM Specialized Disease Collaboration Platform Annual Conference & 10th Jiangsu Traditional Chinese Medicine Academic Conference

6Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Federation of Chinese Medicine & Acupuncture Societies of Australia Sign Strategic Cooperation Framework Agreement

Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Federation of Chinese Medicine & Acupuncture Societies of Australia Sign Strategic Cooperation Framework Agreement

©copyright 2009-2020 Singapore Info Map